Wall Street brokerages predict that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post earnings per share (EPS) of ($1.73) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Agios Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.91) and the highest estimate coming in at ($1.59). Agios Pharmaceuticals reported earnings per share of ($1.19) in the same quarter last year, which suggests a negative year over year growth rate of 45.4%. The company is expected to issue its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.76) per share for the current year, with EPS estimates ranging from ($7.57) to ($6.13). For the next financial year, analysts anticipate that the firm will post earnings of ($6.56) per share, with EPS estimates ranging from ($7.50) to ($5.55). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.15. The company had revenue of $30.20 million during the quarter, compared to analyst estimates of $22.69 million. Agios Pharmaceuticals had a negative return on equity of 48.19% and a negative net margin of 300.63%. The business’s revenue was up 243.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.63) earnings per share.

Several equities analysts have recently commented on AGIO shares. Svb Leerink raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a report on Friday, February 15th. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Wednesday, March 13th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. Piper Jaffray Companies lowered their target price on Agios Pharmaceuticals from $100.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Finally, ValuEngine lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $86.14.

In related news, insider Christopher Bowden sold 10,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $66.57, for a total value of $665,700.00. Following the completion of the transaction, the insider now directly owns 17,238 shares of the company’s stock, valued at approximately $1,147,533.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $67.71, for a total value of $203,130.00. Following the completion of the transaction, the insider now directly owns 29,511 shares of the company’s stock, valued at $1,998,189.81. The disclosure for this sale can be found here. Insiders sold a total of 23,000 shares of company stock valued at $1,510,430 over the last three months. Corporate insiders own 3.16% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. FMR LLC grew its holdings in Agios Pharmaceuticals by 0.3% in the 4th quarter. FMR LLC now owns 8,726,801 shares of the biopharmaceutical company’s stock worth $402,393,000 after buying an additional 27,915 shares in the last quarter. Millennium Management LLC grew its holdings in Agios Pharmaceuticals by 289.7% in the 4th quarter. Millennium Management LLC now owns 215,902 shares of the biopharmaceutical company’s stock worth $9,955,000 after buying an additional 160,493 shares in the last quarter. Geode Capital Management LLC grew its holdings in Agios Pharmaceuticals by 14.6% in the 4th quarter. Geode Capital Management LLC now owns 546,568 shares of the biopharmaceutical company’s stock worth $25,202,000 after buying an additional 69,603 shares in the last quarter. Deutsche Bank AG grew its holdings in Agios Pharmaceuticals by 6.9% in the 4th quarter. Deutsche Bank AG now owns 341,039 shares of the biopharmaceutical company’s stock worth $15,723,000 after buying an additional 21,937 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in Agios Pharmaceuticals by 9.7% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 73,397 shares of the biopharmaceutical company’s stock worth $3,384,000 after buying an additional 6,461 shares in the last quarter.

Shares of NASDAQ:AGIO traded up $0.34 during trading on Friday, hitting $49.25. 9,041 shares of the company traded hands, compared to its average volume of 499,503. The firm has a market capitalization of $2.87 billion, a PE ratio of -8.15 and a beta of 2.33. Agios Pharmaceuticals has a one year low of $41.63 and a one year high of $99.82. The company has a current ratio of 6.89, a quick ratio of 6.86 and a debt-to-equity ratio of 0.11.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Read More: How the Consumer Price Index (CPI) is calculated?

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.